Research ExplorerPublicationsThe impact of the AB0 and the Rhesus blood group system on o...

The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy

Standard

The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. / Engel, Oliver; Soave, Armin; Peine, Sven; Kluth, Luis A; Schmid, Marianne; Shariat, Shahrokh F; Dahlem, Roland; Fisch, Margit; Rink, Michael.

In: WORLD J UROL, Vol. 33, No. 11, 18.03.2015, p. 1769-1776.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Engel, O, Soave, A, Peine, S, Kluth, LA, Schmid, M, Shariat, SF, Dahlem, R, Fisch, M & Rink, M 2015, 'The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy', WORLD J UROL, vol. 33, no. 11, pp. 1769-1776. https://doi.org/10.1007/s00345-015-1531-6

APA

Engel, O., Soave, A., Peine, S., Kluth, L. A., Schmid, M., Shariat, S. F., Dahlem, R., Fisch, M., & Rink, M. (2015). The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. WORLD J UROL, 33(11), 1769-1776. https://doi.org/10.1007/s00345-015-1531-6

Vancouver

Engel O, Soave A, Peine S, Kluth LA, Schmid M, Shariat SF et al. The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. WORLD J UROL. 2015 Mar 18;33(11):1769-1776. https://doi.org/10.1007/s00345-015-1531-6

Bibtex

@article{5851c557c8d54e45a9bc0c334986aeab,
title = "The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy",
abstract = "PURPOSE: To investigate the impact of the AB0 and the Rhesus blood group system on outcomes of urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC).METHODS: We included 511 UCB patients treated with RC without neoadjuvant chemotherapy from 1996 to 2011 at our institution. Cox and logistic regression models assessed the association of the AB0 blood group antigen and Rhesus factor expression with tumor biologic features and outcomes, respectively.RESULTS: In total, 216 patients (42.3 %) had the blood group antigen A0, 73 patients (14.3 %) the antigen B0, 33 patients (6.4 %) the antigen AB and 189 patients (37.0 %) the antigen 00. In addition, 414 patients (81.0 %) were Rhesus factor positive. The AB0 blood group antigen expression was associated with a higher tumor grade (p = 0.003). In contrast, the Rhesus factor was not associated with any clinicopathologic characteristics. Neither the AB0 blood group antigens nor the Rhesus factor was associated with survival. In a sensitivity analysis of patients receiving adjuvant chemotherapy, however, the blood group antigen AB expression was associated with reduced cancer-specific and overall survival.CONCLUSION: The AB0 blood group antigens and the Rhesus factor are not associated with survival. Although the AB0 blood groups and the Rhesus factor are analyzed in every patient treated with RC, they do not represent appropriate biomarkers for UCB outcome prognostication. The association of the AB0 blood group antigens with response to adjuvant chemotherapy requires further validation.",
author = "Oliver Engel and Armin Soave and Sven Peine and Kluth, {Luis A} and Marianne Schmid and Shariat, {Shahrokh F} and Roland Dahlem and Margit Fisch and Michael Rink",
year = "2015",
month = mar,
day = "18",
doi = "10.1007/s00345-015-1531-6",
language = "English",
volume = "33",
pages = "1769--1776",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "11",

}

RIS

TY - JOUR

T1 - The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy

AU - Engel, Oliver

AU - Soave, Armin

AU - Peine, Sven

AU - Kluth, Luis A

AU - Schmid, Marianne

AU - Shariat, Shahrokh F

AU - Dahlem, Roland

AU - Fisch, Margit

AU - Rink, Michael

PY - 2015/3/18

Y1 - 2015/3/18

N2 - PURPOSE: To investigate the impact of the AB0 and the Rhesus blood group system on outcomes of urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC).METHODS: We included 511 UCB patients treated with RC without neoadjuvant chemotherapy from 1996 to 2011 at our institution. Cox and logistic regression models assessed the association of the AB0 blood group antigen and Rhesus factor expression with tumor biologic features and outcomes, respectively.RESULTS: In total, 216 patients (42.3 %) had the blood group antigen A0, 73 patients (14.3 %) the antigen B0, 33 patients (6.4 %) the antigen AB and 189 patients (37.0 %) the antigen 00. In addition, 414 patients (81.0 %) were Rhesus factor positive. The AB0 blood group antigen expression was associated with a higher tumor grade (p = 0.003). In contrast, the Rhesus factor was not associated with any clinicopathologic characteristics. Neither the AB0 blood group antigens nor the Rhesus factor was associated with survival. In a sensitivity analysis of patients receiving adjuvant chemotherapy, however, the blood group antigen AB expression was associated with reduced cancer-specific and overall survival.CONCLUSION: The AB0 blood group antigens and the Rhesus factor are not associated with survival. Although the AB0 blood groups and the Rhesus factor are analyzed in every patient treated with RC, they do not represent appropriate biomarkers for UCB outcome prognostication. The association of the AB0 blood group antigens with response to adjuvant chemotherapy requires further validation.

AB - PURPOSE: To investigate the impact of the AB0 and the Rhesus blood group system on outcomes of urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC).METHODS: We included 511 UCB patients treated with RC without neoadjuvant chemotherapy from 1996 to 2011 at our institution. Cox and logistic regression models assessed the association of the AB0 blood group antigen and Rhesus factor expression with tumor biologic features and outcomes, respectively.RESULTS: In total, 216 patients (42.3 %) had the blood group antigen A0, 73 patients (14.3 %) the antigen B0, 33 patients (6.4 %) the antigen AB and 189 patients (37.0 %) the antigen 00. In addition, 414 patients (81.0 %) were Rhesus factor positive. The AB0 blood group antigen expression was associated with a higher tumor grade (p = 0.003). In contrast, the Rhesus factor was not associated with any clinicopathologic characteristics. Neither the AB0 blood group antigens nor the Rhesus factor was associated with survival. In a sensitivity analysis of patients receiving adjuvant chemotherapy, however, the blood group antigen AB expression was associated with reduced cancer-specific and overall survival.CONCLUSION: The AB0 blood group antigens and the Rhesus factor are not associated with survival. Although the AB0 blood groups and the Rhesus factor are analyzed in every patient treated with RC, they do not represent appropriate biomarkers for UCB outcome prognostication. The association of the AB0 blood group antigens with response to adjuvant chemotherapy requires further validation.

U2 - 10.1007/s00345-015-1531-6

DO - 10.1007/s00345-015-1531-6

M3 - SCORING: Journal article

C2 - 25782867

VL - 33

SP - 1769

EP - 1776

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 11

ER -